Type to search

AZD1222 US Phase III Primary Analysis Confirms Vaccine Safety and Efficacy | Pharmtech Focus
COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials | Pharmtech Focus